Molecular Partners AG (MOLN) stock
Close on Nov 11, 2026Market cap $124.76MP/E –Yield –
Molecular Partners AG saw revenue fall 100.0% to CHF 0 over fiscal 2025. Free cash flow was -CHF 51.97M. At the latest close the market valued the company at CHF 102.20M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- CHF 102.20M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -50.85%
Fundamentals
- Revenue
- CHF 0
- EPS, diluted
- -1.65 CHF
- Free cash flow
- -CHF 51.97M
- Diluted shares
- 38M
Trading
- Previous close
- $3.09
- Open
- $3.09
- Day's range
- $3.09 – $3.09
- Volume
- 460
- Average volume (20 days)
- 2,161
- Beta (5 years)
- 0.90
- RSI (14 days)
- 31.8
- Volatility (1 year)
- 51.4%
- Relative volume
- 0.24×
- WACC
- 9.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MOLN | S&P 500 | Difference | MOLN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.7% | -2.4% | −17.3 pts | ||
| 3 months | -25.2% | -1.2% | −24.0 pts | ||
| Year to date | -29.1% | +12.3% | −41.4 pts | ||
| 1 year | -23.3% | +12.4% | −35.8 pts | ||
| 3 years | -25.5% | +78.8% | −104.3 pts | -9.3% | +21.4% |
| 5 years | -78.9% | +75.2% | −154.1 pts | -26.7% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025, CHF
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Molecular Partners filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Molecular Partners
Biological Products, (No Diagnostic Substances)
Molecular Partners AG is a clinical-stage biotechnology company that designs and develops Designed Ankyrin Repeat Protein (DARPin) therapeutics. The company concentrates primarily on oncology treatments, engineering custom protein drug candidates with distinct mechanisms of action. Its pipeline includes targeted radiopharmaceuticals such as Radio-DARPins and next-generation immune cell engagers like Switch-DARPins. Key investigational programs encompass MP0712, MP0726, MP0317, and MP0533, which target specific antigens in solid tumors and hematologic malignancies. Rather than serving direct retail customers, the company targets cancer patient populations and advances its programs both independently and through strategic co-development agreements with biopharmaceutical partners.
Company profile, executives and historyMolecular Partners stock: common questions
What is Molecular Partners's stock price?
MOLN closed at $3.09 on Nov 11, 2026, up 0.00% on the day.
What is Molecular Partners's market cap?
Molecular Partners was worth $124.76M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MOLN's P/E ratio?
Molecular Partners lost money over fiscal 2025 (diluted EPS -1.65 CHF), so it has no meaningful P/E ratio.
How much revenue does Molecular Partners make?
Molecular Partners reported revenue of CHF 0 for fiscal 2025, down 100.0% from a year earlier.
Does Molecular Partners pay a dividend?
No. Molecular Partners has not paid a cash dividend over the last twelve months.
How has MOLN stock performed over the past year?
Including dividends, MOLN returned -23.3% over the past year, against +12.4% for the S&P 500.
Who are Molecular Partners's competitors?
Companies most similar to Molecular Partners by business, industry and size include CRIS, IPHA, TCRX, RLAY, ELOX.
See a number that looks wrong?